A double blind, randomised, placebo controlled, multicentre trial of anti-tumour necrotising factor alpha (anti-TNF alpha) chimeric monoclonal antibody (infliximab, Remicade) in combination with methotrexate in patients with very early inflammatory arthritis

Trial Profile

A double blind, randomised, placebo controlled, multicentre trial of anti-tumour necrotising factor alpha (anti-TNF alpha) chimeric monoclonal antibody (infliximab, Remicade) in combination with methotrexate in patients with very early inflammatory arthritis

Completed
Phase of Trial: Phase II/III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Infliximab (Primary) ; Methotrexate
  • Indications Arthritis
  • Focus Therapeutic Use
  • Acronyms DINORA
  • Most Recent Events

    • 17 Jun 2017 Results (n=90) presented at the 18th Annual Congress of the European League Against Rheumatism
    • 06 Nov 2010 Additional trial investigator (Scott DL) added as reported by United Kingdom Clinical Research Network record.
    • 23 Sep 2010 Planned end date changed from 15 Sep 2011 to 1 Jul 2012 as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top